TWI646969B - 乳凝集素及/或其分解物之用途 - Google Patents
乳凝集素及/或其分解物之用途 Download PDFInfo
- Publication number
- TWI646969B TWI646969B TW103108236A TW103108236A TWI646969B TW I646969 B TWI646969 B TW I646969B TW 103108236 A TW103108236 A TW 103108236A TW 103108236 A TW103108236 A TW 103108236A TW I646969 B TWI646969 B TW I646969B
- Authority
- TW
- Taiwan
- Prior art keywords
- infection
- lactadherin
- milk
- lectin
- product
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 22
- 239000008267 milk Substances 0.000 title claims abstract description 22
- 210000004080 milk Anatomy 0.000 title claims abstract description 22
- 102000004856 Lectins Human genes 0.000 title claims description 26
- 108090001090 Lectins Proteins 0.000 title claims description 26
- 239000002523 lectin Substances 0.000 title claims description 26
- 238000000354 decomposition reaction Methods 0.000 title 1
- 102100039648 Lactadherin Human genes 0.000 claims abstract description 21
- 101710191666 Lactadherin Proteins 0.000 claims abstract description 21
- 102000035195 Peptidases Human genes 0.000 claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 35
- 206010022000 influenza Diseases 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 229960001322 trypsin Drugs 0.000 claims description 7
- 239000003223 protective agent Substances 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- 235000020247 cow milk Nutrition 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 51
- 239000011814 protection agent Substances 0.000 abstract description 19
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 230000009385 viral infection Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 8
- 239000007857 degradation product Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 108010063045 Lactoferrin Proteins 0.000 description 5
- 102000010445 Lactoferrin Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 5
- 235000021242 lactoferrin Nutrition 0.000 description 5
- 229940078795 lactoferrin Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001471 micro-filtration Methods 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 101710146024 Horcolin Proteins 0.000 description 3
- 101710189395 Lectin Proteins 0.000 description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 3
- 239000000910 agglutinin Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710180012 Protease 7 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004770 highest occupied molecular orbital Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000285721 Ibaraki virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101100190054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX8 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
一種感染防護劑，其含有乳凝集素(lactadherin)及/或乳凝集素經蛋白質分解酵素處理所得之分解物作為有效成分。感染防護劑由於係以哺乳類之乳為原料，可簡便且經濟地製造，並可在日常中安全地攝取。
Description
本發明係有關於對抗流感病毒之感染防護效果優異，有用於流感的預防或治療，且穩定性及安全性優良的感染防護劑。本發明進一步有關於含有感染防護劑的感染防護用飲食品、感染防護用營養組成物或感染防護用飼料。
流感病毒係由空氣中感染至人體，年復一年引起流行。近年來，因衛生方面的改善或醫學的進步，其威脅已然減少，但仍舊有致命之案例。流感病毒有A型、B型、C型此三種，其中，A型病毒容易發生突變，而容易引起稱之為「泛流行(pandemic)」的全球性大流行。針對流感病毒感染的預防主要係藉由接種疫苗來進行。然而，由於流感病毒容易發生抗原轉移或抗原飄移等突變，因此流行之病毒與疫苗之抗原經常不一致，現況在於疫苗所產生的預防效果未必得以滿足。因此，目前在日本，對兒童預防接種疫苗仍未予強制實施。再者，作為流感之治療藥可列舉阿曼它定(amantadine)或奧司他韋(Oseltamivir)、扎那米韋(Zanamivir)等，惟需考量幻覺或睡眠障礙等副作用或抗藥菌的出現等問題，在其使用上需充分注意。基於此種狀況，即有待開發出一種在日常中可安全地攝取，並可望達到流感的預防或治療之類的飲食品或飼料。
作為具有對抗流感病毒之感染防護效果的食品成分，迄今已知使使凝乳酶或胃蛋白作用於神經鞘磷脂或乳鐵蛋白、κ-乾酪素所生成之屬胜肽的κ-乾酪素醣巨胜肽(κ-casein glyco-macropeoptide)。此外，亦已知屬發酵乳等所含乳酸菌的一種的保加利亞乳酸桿菌1073R-1在菌體外產生的多糖會作用於腸管使IgA之產量增加，同時經由培氏淋巴結(Peyer’s patches)使NK活性上升，而具有對抗流感病毒之感染防護效果。
乳凝集素為構成乳之脂肪球膜的糖蛋白之一，在牛乳中，係占有脂肪球膜所含之蛋白質的約10%。其分子量為43kDa~53kDa、等電點為7.0，具有類表皮生長因子的兩個分域。又，乳凝集素在牛亦稱為PAS-VI-VII(PAS6/7)，小鼠的乳汁所含之乳凝集素亦表現為「MFG-E8」。更者，乳凝集素被認為可擔負調整新生兒消化道機能之作用，為了防止新生兒被輪狀病毒感染而摻混於育嬰用人工奶粉中。然而，乳凝集素及/或其分解物有對抗流感病毒之感染防護效果尚未為人所知悉。
【先前技術文獻】
【專利文獻】
【專利文獻1】日本特開2008-37788
【非專利文獻】
【非專利文獻1】Bioscience,Biotechnology and Biochemistry,57,1214-1215,1993
【非專利文獻2】International Immunopharmacology,11,2246-2250,2011
本發明之課題為提供一種具有對抗流感病毒之感染防護效果，有用於預防或治療之感染防護劑、及摻混有該感染防護劑之感染防護用飲食品、感染防護用營養組成物或感染防護用飼料。
本案發明人等為解決上述課題而致力進行研究的結果發現，乳凝集素及/或其分解物有優良的對抗流感病毒之感染防護效果。即，本發明包含以下態樣：
(1)一種對抗流感病毒之感染防護劑，其係以乳凝集素及/或其分解物為有效成分。
(2)如(1)之對抗流感病毒之感染防護劑，其中，乳凝集素及/或其分解物係源自於牛乳。
(3)如(1)或(2)之對抗流感病毒之感染防護劑，其中，乳凝集素分解物係將乳凝集素使用蛋白質分解酵素予以分解而得。
(4)如(3)之對抗流感病毒之感染防護劑，其中，蛋白質分解酵素係選自於由胰蛋白酶、胰酶、胰凝乳蛋白酶、胃蛋白酶、木瓜酶構成之群組中的至少1種。
(5)一種感染防護用飲食品、感染防護用營養組成物或感染防護用飼料，其含有如(1)至(4)中任一項之對抗流感病毒之感染防護劑。
(6)一種對抗流感病毒之感染防護方法，其係藉由經口攝取如(1)至(4)中任一項之感染防護劑。
(7)一種感染防護劑之使用方法，其係將以乳凝集素及/或其分解物為有效成分的感染防護劑應用於流感病毒感染患者。
本發明之感染防護劑其對抗流感病毒之感染防護效果顯著，有用於流感的預防或治療。
作為感染防護劑之有效成分的乳凝集素可藉由例如對(A)屬由生乳製造黃油(butter)時所生成之水相成分的酪乳(butter milk)、(B)將生乳其藉分離器分離所得之脂肪成分40~50%的乳油(cream)再度以分離器分離而得之60%以上的高脂肪乳油，進行加熱處理或者剪切處理，於高脂肪乳油相轉換時所排出的水相成分、或(C)屬將黃油加熱溶解時所分離之水相成分的黃油乳清，使用超過濾(UF)膜或微過濾(MF)膜、逆滲透膜(RO)膜、離子交換樹脂等進行脫鹽或濃縮而得。此外，可藉由對黃油乳清添加鹽酸將pH調整成4.4後，添加氯化鈣，於50℃保持30分鐘而分離出沉澱物，將其再度溶解或懸浮於水等之後，使用超過濾(UF)膜或微過濾(MF)膜、逆滲透膜(RO)膜、離子交換樹脂等進行脫鹽或濃縮而得。更且，作為感染防護劑之有效成分的乳凝集素分解物，可藉由將上述乳凝集素以任意蛋白質分解酵素予以分解而得。作為蛋白質分解酵素，除Protease A「Amano」SD(商
品名)、THERMOASE PC10F(商品名)、PROTIN SD-AY10(商品名)等市售之食品．工業用蛋白酶劑外，尚可列示胰蛋白酶、胰酶、胰凝乳蛋白酶、胃蛋白酶、木瓜酶等，且亦可將使此多種組合使用。如上述所調製的乳凝集素及/或其分解物亦可藉由冷凍乾燥或噴霧乾燥等乾燥。
乳凝集素及/或其分解物可使用取自人類、牛、水牛、山羊、綿羊等哺乳類之乳汁所調製者、藉基因工程方法所生產者、由血液或內臟器官所精製者等。其原因在於可簡便且經濟地製造，並可在日常中安全地攝取之故。其中，較佳為源自於牛乳者。又，亦可使用經精製且於市售的乳凝集素及/或其分解物之試劑。
乳凝集素及/或其分解物可直接作為感染防護劑使用，惟亦可視需求，依循常用方法，製劑化成粉末劑、顆粒劑、錠劑、膠囊劑、飲料劑等而使用。又，以藉由冷凍乾燥或噴霧乾燥等乾燥的乳凝集素及/或其分解物而言，亦可直接作為感染防護劑使用，也可依循常用方法，經製劑化而使用。
更且，將此等製劑化後，亦可將其摻混於營養劑或優格、飲料、鬆餅等飲食品、營養組成物或飼料中。
感染防護用飲食品、感染防護用營養組成物及感染防護用飼料，除該乳凝集素及/或其分解物外，尚可含有安定劑或糖類、脂質、香料、維生素、礦物質、類黃酮、多酚等其他飲食品、飼料通常所含有的原料等。又，除作為有效成分的乳凝集素及/或其分解物外，尚可與顯示感染防護作用的成分，例如神經鞘磷脂或乳鐵蛋白等一齊使用。
對於感染防護用飲食品、感染防護用營養組成物及感染防護用飼料中之乳凝集素及/或其分解物的摻混量，不特別限制，為發揮對抗流感病毒之感染防護效果，係以按成人每人每日經口攝取0.1mg以上之乳凝集素及/或其分解物的方式來調整對醫藥品或飲食品、飼料之摻混量為較佳。
感染防護劑可藉由對作為有效成分的乳凝集素及/或其分解物添加適當的助劑而製劑化成任意形態。於製劑化之際，可採用通常使用的填充劑、增量劑、黏結劑、崩解劑、界面活性劑、潤滑劑等稀釋劑或賦形劑。作為賦形劑，可添加例如蔗糖、乳糖、澱粉、結晶性纖維素、甘露醇、輕質矽酸酐、鋁酸鎂、合成矽酸鋁、偏矽酸鎂鋁、碳酸鈣、碳酸氫鈉、磷酸氫鈣、羧甲基纖維素鈣等的1種或組合2種以上。
諸如上述，本發明係以實施形態記載，惟構成該揭示一部分的論述不應理解為將本發明加以限定。由該揭示，本領域具有通常知識者可明瞭各種替代實施形態、實施例及運用技術。
舉例言之，茲提供一種將以實施形態中所說明之乳凝集素及/或其分解物為有效成分的感染防護劑應用於流感病毒感染患者的感染防護劑之使用方法。此時，作為乳凝集素及/或其分解物，可使用例如如後述實施例欄所說明之自原料分離、精製而成者。又，感染防護劑亦可應用於人類以外的哺乳類，諸如犬、猴、貓、牛、馬、豬、雞、羊等家畜。
以下示出實施例、試驗例對本發明詳細加以說明，惟此等僅供列示，本發明不受此等任何限定。
【實施例1】
對10kg經冷凍乾燥的未殺菌之酪乳粉末添加100kg丙酮後，以夸克分離器(Quark separator)施予處理，藉此將沉澱物完全去除而得到上清液。利用蒸發器自上清液中去除丙酮並再度予以溶解於去離子水後，以區分分子量60kDa之超過濾膜加以處理，並回收透過液。其次，將該透過液以區分分子量30kDa之超過濾膜去除雜質，並進行脫鹽、濃縮後，予以冷凍乾燥而得到68g乳凝集素之粉末(實施例品1)。該乳凝集素之粉末中含有78%乳凝集素。如此所得乳凝集素可直接作為感染防護劑使用。
【實施例2】
將500mg實施例1中調製之乳凝集素之粉末溶解於100ml精製水，並使用小蘇打將pH調整至8。其後，添加作為蛋白質分解酵素的胰蛋白酶(SIGMA公司製)使最終濃度成為0.01%，於37℃實施1小時酵素處理。接著，於85℃實施10分鐘加熱處理使酵素去活化後，予以冷凍乾燥而得到463mg乳凝集素分解物之粉末(實施例品2)。如此所得乳凝集素分解物之分子量為5kDa以下，可直接作為感染防護劑使用。
【實施例3】
將10g實施例1中調製之乳凝集素之粉末溶解於200ml精製水後，予以保持於45℃，加入2g之Protease A「Amano」SD(Amano Enzyme公司製)，實施2小時酵素處理。接著，於80℃實施10分鐘加熱處理使酵素去活化後，予以冷凍乾燥而得到8.2g乳凝集素分解物之粉末(實施例品3)。如此所得乳凝集素分解物之分子量為5kDa以下，可直接作為感染防護劑使用。
【試驗例1】
(對抗流感病毒之感染預防效果的確認)
使作為A型流感病毒的A/Guinzhou病毒、作為B型流感病毒的B/Ibaraki病毒經鼻感染小鼠(Balb/c；公；6週大)，同時將溶有實施例品1之乳凝集素成為100μg/ml的溶液與溶有實施例品2之乳凝集素分解物成為100μg/ml的溶液，分別以1μl/鼻腔內投予量(投予量：0.1μg)進行經鼻投予，並將對抗流感病毒之感染預防效果，與經各流感病毒單獨經鼻感染的群(控制組)，使用鼻腔內清洗液中的病毒力價進行比較驗證。此外，判定係採用使用MDCK細胞的噬菌斑法(plaque method)。將其結果示於表1。
數值表示平均值±標準差(n=8)。
※表示與各控制組比較顯著較低(p<0.05)。
據表1之結果，藉由鼻腔內投予乳凝集素及其分解物，對A型、B型均可確認感染預防效果，特別是對抗A型流感病毒之效果顯著。
【試驗例2】
(經口投予之流感病毒之感染預防效果的確認)
使流感病毒PR8(H1N1)以1×103pfu之病毒量感染小鼠(Balb/c；公；6週大)。於感染前，分成使用實施例品1與實施例品3依小鼠每1kg體重經口投予0.1mg乳凝集素或其分解物之群、及經口投予10mg乳凝集素或其分解物之群，以病毒感染3日後之鼻腔清洗液中的病毒力價來判定對抗流感病毒之感染預防效果。
又，作為陽性對照，係於感染前，設定經口投予10mg乳鐵蛋白之群，並與僅經口投予作為溶媒的水之群(控制組)，採用使用MDCK細胞的噬菌斑法進行比較驗證。將其結果示於表2。
數值表示平均值±標準差(n=10)。
※1表示與各控制組比較顯著較低(p<0.05)。
※2表示與10mg乳鐵蛋白比較顯著較低(p<0.05)。
據表2之結果，藉由經口投予乳凝集素或其分解物，相較於控制組，鼻腔內病毒力價顯著降低。又，該效果比起同樣經口投予之乳鐵蛋白顯著提高。由此結果可知，乳凝集素及其分解物有對抗流感病毒之優良感染防護效果。又，該作用在小鼠每1kg體重經口投予0.1mg以上時可明確確認。
【實施例4】
(流感病毒感染預防用膠囊劑的調製)
以表3所示摻混量混合原料後，依常用方法進行造粒並予以填充於膠囊中，製成流感病毒感染防護用膠囊劑。
【實施例5】
(流感病毒感染預防用錠劑的調製)
以表4所示摻混量混合原料後，依常用方法成型為1g，並進行打錠而製成感染防護用錠劑。
【實施例6】
(流感病毒感染預防用液狀營養組成物的調製)
將50g之實施例品1溶解於4,950g之去離子水，予以加熱至50℃後，利用TK HOMO MIXER(TK ROBO MICS；特殊機化工業公司製)，以6,000rpm攪拌混合30分鐘而得到乳凝集素含量39g/5kg之乳凝集素溶液。對5.0kg該乳凝集素溶液，摻混5.0kg乾酪素、5.0kg大豆蛋白質、1.0kg魚油、3.0kg紫蘇油、17.0kg糊精、6.0kg礦物質混合物、1.95kg維生素混合物、2.0kg乳化劑、4.0kg安定劑、0.05kg香料，予以填充至200ml之蒸煮袋，並利用殺菌釜滅菌機(第1種壓力容器；TYPE：RCS-4CRTGN；日阪製作所製)以121℃、20分鐘進行殺菌，製成50kg流感病毒感染預防用液狀營養組成物。
【實施例7】
(流感病毒感染預防用飲料的調製)
將300g脫脂奶粉溶解於409g之去離子水後，溶解1g實施例品2並予以加熱至50℃後，利用ULTRA DISPERSER(ULTRA-TURRAX T-25；IKA JAPAN公司製)，以9,500rpm攪拌混合30分鐘。添加100g麥芽糖醇、2g酸味料、20g還原糖漿、2g香料、166g去離子水後，予以填充至100ml之玻璃瓶，以95℃、15秒鐘進行殺菌後予以密封，而調製成流感病毒感染預防用飲料10瓶(內容量100ml)。
【實施例8】
(犬用流感病毒感染預防用飼料的調製)
將2kg之實施例品1溶解於98kg之去離子水，予以加熱至50℃後，利用TK HOMO MIXER(MARK II 160型；特殊機化工業製)，以3,600rpm攪拌混合40分鐘而得到乳凝集素含量1.56g/100g之乳凝集素溶液。對10kg該乳凝集素溶液摻混12kg大豆粕、14kg脫脂奶粉、4kg大豆油、2kg玉米油、23.2kg棕櫚油、14kg玉米
澱粉、9kg小麥粉、2kg米糠、5kg維生素混合物、2.8kg纖維素、2kg礦物質混合物，以120℃、4分鐘進行殺菌，製成100kg流感病毒感染預防用飼料。
Claims (4)
- 一種乳凝集素及/或其分解物之用途，係用於製造對抗流感病毒之感染防護劑，該對抗流感病毒之感染防護劑係以經精製之乳凝集素及/或其分解物為有效成分，成人每人每日經口攝取0.1mg以上之該乳凝集素及/或其分解物。
- 如申請專利範圍第1項之乳凝集素及/或其分解物之用途，其中，該乳凝集素及/或其分解物係源自於牛乳。
- 如申請專利範圍第1或2項之乳凝集素及/或其分解物之用途，其中，該乳凝集素分解物係將乳凝集素使用蛋白質分解酵素予以分解而得。
- 如申請專利範圍第3項之乳凝集素及/或其分解物之用途，其中，該蛋白質分解酵素係選自於由胰蛋白酶、胰酶、胰凝乳蛋白酶、胃蛋白酶、木瓜酶構成之群組中的至少1種。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013046737A JP6346405B2 (ja) | 2013-03-08 | 2013-03-08 | 感染予防剤 |
| JP2013-046737 | 2013-03-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201446257A TW201446257A (zh) | 2014-12-16 |
| TWI646969B true TWI646969B (zh) | 2019-01-11 |
Family
ID=51491438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103108236A TWI646969B (zh) | 2013-03-08 | 2014-03-10 | 乳凝集素及/或其分解物之用途 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP6346405B2 (zh) |
| CN (1) | CN105025914B (zh) |
| AU (1) | AU2014226864B2 (zh) |
| MY (1) | MY179921A (zh) |
| NZ (1) | NZ711985A (zh) |
| TW (1) | TWI646969B (zh) |
| WO (1) | WO2014136931A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016104642A1 (ja) * | 2014-12-25 | 2016-06-30 | 一般財団法人糧食研究会 | 乳化安定剤及びそれを用いた乳化安定化方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100168366A1 (en) * | 2007-06-28 | 2010-07-01 | Shizuoka Prefectural Universities Corporation | Novel synthetic n-linked sialo-glycan-containing polymer and method for producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5130598B2 (ja) * | 2005-09-02 | 2013-01-30 | 静岡県公立大学法人 | ウイルスレセプター糖鎖認識特異性の判別方法 |
| JP2008031156A (ja) * | 2006-07-07 | 2008-02-14 | National Univ Corp Shizuoka Univ | 抗ウイルス剤 |
| EP2389952A1 (en) * | 2010-05-31 | 2011-11-30 | Rotalactis Srl | Lactadherin-derived peptides as antiviral agents |
| EP2701730A4 (en) * | 2011-04-28 | 2015-05-27 | The Feinstein Inst Medical Res | MFG-E8 AND USES THEREOF |
-
2013
- 2013-03-08 JP JP2013046737A patent/JP6346405B2/ja active Active
-
2014
- 2014-03-07 NZ NZ711985A patent/NZ711985A/en not_active IP Right Cessation
- 2014-03-07 WO PCT/JP2014/055931 patent/WO2014136931A1/ja not_active Ceased
- 2014-03-07 CN CN201480012689.8A patent/CN105025914B/zh not_active Expired - Fee Related
- 2014-03-07 MY MYPI2015702737A patent/MY179921A/en unknown
- 2014-03-07 AU AU2014226864A patent/AU2014226864B2/en not_active Ceased
- 2014-03-10 TW TW103108236A patent/TWI646969B/zh not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100168366A1 (en) * | 2007-06-28 | 2010-07-01 | Shizuoka Prefectural Universities Corporation | Novel synthetic n-linked sialo-glycan-containing polymer and method for producing the same |
Non-Patent Citations (2)
| Title |
|---|
| Inagaki, Mizuho, et al. "The bovine lactophorin C-terminal fragment and PAS6/7 were both potent in the inhibition of human rotavirus replication in cultured epithelial cells and the prevention of experimental gastroenteritis." Bioscience, biotechnology, and biochemistry 74.7 (2010): 1386-1390. * |
| Newburg, David S., et al. "Role of human-milk lactadherin in protectoin against symptomatic rotavirus infection." The Lancet 351.9110 (1998): 1160-1164. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014226864B2 (en) | 2018-09-13 |
| HK1210942A1 (zh) | 2016-05-13 |
| CN105025914A (zh) | 2015-11-04 |
| WO2014136931A1 (ja) | 2014-09-12 |
| TW201446257A (zh) | 2014-12-16 |
| JP2014172862A (ja) | 2014-09-22 |
| JP6346405B2 (ja) | 2018-06-20 |
| NZ711985A (en) | 2020-06-26 |
| CN105025914B (zh) | 2020-02-18 |
| AU2014226864A1 (en) | 2015-09-24 |
| MY179921A (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI539902B (zh) | 脂質代謝改善劑 | |
| TWI483684B (zh) | 肌肉增強劑 | |
| US20120329991A1 (en) | Agent for preventing muscle atrophy | |
| JP5465834B2 (ja) | 肝機能保護剤 | |
| TWI566704B (zh) | 骨強化劑、使用該骨強化劑之製品及骨強化方法 | |
| JP6009181B2 (ja) | 骨強化剤 | |
| TWI646969B (zh) | 乳凝集素及/或其分解物之用途 | |
| JP5695326B2 (ja) | タンパク質合成促進剤 | |
| JP5969225B2 (ja) | 骨強化剤 | |
| TWI686204B (zh) | 源自乳汁之鹼性蛋白質級分及/或源自乳汁之鹼性蛋白質級分分解物、與乳清蛋白質水解物之用途 | |
| HK1210942B (zh) | 感染防御剂 | |
| WO2014020675A1 (ja) | 新規タンパク質素材 | |
| TW201511769A (zh) | 消炎劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |